Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients
Luigi Angelo Vaira(University of Sassari), Giacomo De Riu(University of Sassari), Sebastiano Cutrupi(National Research Council), Sven Saussez(Centre Hospitalier Universitaire de Saint-Pierre), Jérôme R. Lechien(Centre National de la Recherche Scientifique), Carlos M. Chiesa‐Estomba(Biogipuzkoa Health Research Institute), Giovanni Salzano, Claire Hopkins(Guy's and St Thomas' NHS Foundation Trust), Marzia Petrocelli(Azienda USL di Bologna)
Cited by 101
Related Papers
Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study
|European Archives of Oto-Rhino-Laryngology|2020|2.8k
Clinical and epidemiological characteristics of 1420 European patients with mild‐to‐moderate coronavirus disease 2019
|Journal of Internal Medicine|2020|847
Adiponectin, Metabolic Risk Factors, and Cardiovascular Events among Patients with End-Stage Renal Disease
|Journal of the American Society of Nephrology|2002|761
Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease
|Circulation|2002|522
Vitamin D levels and patient outcome in chronic kidney disease
|Kidney International|2008|436